{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:27:34Z","timestamp":1792466854098,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41375-025-02703-6","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T07:35:36Z","timestamp":1754033736000},"page":"2375-2383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific tools"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0201-0547","authenticated-orcid":false,"given":"Sylvain","family":"Moinard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4890-336X","authenticated-orcid":false,"given":"Benjamin","family":"Lebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5321-3195","authenticated-orcid":false,"given":"Tom","family":"Lachaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyacinthe","family":"Johnson-Ansah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Doublet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9270-9472","authenticated-orcid":false,"given":"Gabrielle","family":"Roth-Guepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Rigal-Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Parry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1708-8606","authenticated-orcid":false,"given":"Mathieu","family":"Meunier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8275-5686","authenticated-orcid":false,"given":"Am\u00e9lie","family":"Penot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9567-7879","authenticated-orcid":false,"given":"Laurence","family":"Legros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Pante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Escoffre-Barbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0434-265X","authenticated-orcid":false,"given":"Guillaume","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7516-6914","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Monjanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4853-8227","authenticated-orcid":false,"given":"Dalil","family":"Hamroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdessattar","family":"Khlaifia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1689-9965","authenticated-orcid":false,"given":"Jo\u00e9vin","family":"Besombes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1781-1323","authenticated-orcid":false,"given":"C\u00e9line","family":"Bourgne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc G.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"2703_CR1","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"2703_CR2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in \u2018good-risk\u2019 chronic granulocytic leukemia. Blood. 1984;63:789\u201399.","journal-title":"Blood"},{"key":"2703_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","volume":"30","author":"M Pfirrmann","year":"2016","unstructured":"Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30:48\u201356.","journal-title":"Leukemia"},{"key":"2703_CR4","doi-asserted-by":"publisher","first-page":"8931","DOI":"10.1002\/cam4.3516","volume":"9","author":"E Sato","year":"2020","unstructured":"Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, et al. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort. Cancer Med. 2020;9:8931\u20139.","journal-title":"Cancer Med"},{"key":"2703_CR5","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41375-021-01387-y","volume":"36","author":"XS Zhang","year":"2022","unstructured":"Zhang XS, Gale RP, Huang XJ, Jiang Q. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?. Leukemia. 2022;36:482\u201391.","journal-title":"Leukemia"},{"key":"2703_CR6","doi-asserted-by":"crossref","unstructured":"Saugues S, Lambert C, Daguenet E, Roth-Guepin G, Huguet F, Cony-Makhoul P, et al. The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort. Haematologica. 2024;109:2893-2907.","DOI":"10.3324\/haematol.2023.284860"},{"key":"2703_CR7","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41375-022-01527-y","volume":"36","author":"XS Zhang","year":"2022","unstructured":"Zhang XS, Gale RP, Zhang MJ, Huang XJ, Jiang Q. A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy. Leukemia. 2022;36:1336\u201342.","journal-title":"Leukemia"},{"key":"2703_CR8","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1182\/blood.2024024761","volume":"144","author":"X Zhang","year":"2024","unstructured":"Zhang X, Liu B, Huang J, Zhang Y, Xu N, Gale RP, et al. A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Blood. 2024;144:1951\u201361.","journal-title":"Blood"},{"key":"2703_CR9","doi-asserted-by":"crossref","unstructured":"Lauseker M, Hoffmann VS, Pfirrmann M Prognostic scoring systems in chronic myeloid leukaemia. Leukemia. 2025;39:1046-52.","DOI":"10.1038\/s41375-025-02606-6"},{"key":"2703_CR10","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/sim.7501","volume":"36","author":"PC Austin","year":"2017","unstructured":"Austin PC, Fine JP. Practical recommendations for reporting F ine- G ray model analyses for competing risk data. Stat Med. 2017;36:4391\u2013400.","journal-title":"Stat Med"},{"key":"2703_CR11","doi-asserted-by":"crossref","unstructured":"Gray RJ A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk. Ann Stat [Internet]. 1988 Sep 1 [cited 2025 Jun 2];16(3). Available from: https:\/\/projecteuclid.org\/journals\/annals-of-statistics\/volume-16\/issue-3\/A-Class-of-K-Sample-Tests-for-Comparing-the-Cumulative\/10.1214\/aos\/1176350951.full","DOI":"10.1214\/aos\/1176350951"},{"key":"2703_CR12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837.","journal-title":"Biometrics"},{"key":"2703_CR13","doi-asserted-by":"publisher","first-page":"e391","DOI":"10.1016\/j.clml.2018.06.031","volume":"18","author":"H Kim","year":"2018","unstructured":"Kim H, Kim S, Kim HJ, Kim YK, Kwak JY, Yhim HY, et al. Comparison of frequency and sensitivity of BCR-ABL1 kinase domain mutations in Asian and white patients with imatinib-resistant chronic\u2013phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2018;18:e391\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2703_CR14","first-page":"302","volume":"74","author":"E Lim","year":"2015","unstructured":"Lim E, Miyamura J, Chen JJ. Racial\/ethnic-specific reference intervals for common laboratory tests: a comparison among Asians, Blacks, Hispanics, and Whites. Hawaii J Med Public Health J Asia Pac Med Public Health. 2015;74:302\u201310.","journal-title":"Hawaii J Med Public Health J Asia Pac Med Public Health"},{"key":"2703_CR15","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.3390\/cancers14235752","volume":"14","author":"S Hu","year":"2022","unstructured":"Hu S, Chen D, Xu X, Zhang L, Wang S, Jin K, et al. Targeted next-generation sequencing identifies additional mutations other than BCR\u2237ABL in chronic myeloid leukemia patients: a Chinese Monocentric Retrospective Study. Cancers. 2022;14:5752.","journal-title":"Cancers"},{"key":"2703_CR16","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","volume":"121","author":"S Branford","year":"2013","unstructured":"Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK, et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013;121:3818\u201324.","journal-title":"Blood"},{"key":"2703_CR17","doi-asserted-by":"publisher","first-page":"7534","DOI":"10.18632\/oncotarget.23691","volume":"9","author":"M Breccia","year":"2018","unstructured":"Breccia M, Molica M, Colafigli G, Massaro F, Quattrocchi L, Latagliata R, et al. Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib. Oncotarget. 2018;9:7534\u201340.","journal-title":"Oncotarget"},{"key":"2703_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41388-024-03197-9","volume":"44","author":"C Zhang","year":"2025","unstructured":"Zhang C, Hao T, Bortoluzzi A, Chen MH, Wu X, Wang J, et al. Sex-dependent differences in hematopoietic stem cell aging and leukemogenic potential. Oncogene. 2025;44:64\u201378.","journal-title":"Oncogene"},{"key":"2703_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/ajh.24943","volume":"93","author":"A Alhuraiji","year":"2018","unstructured":"Alhuraiji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, et al. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol. 2018;93:84\u201390.","journal-title":"Am J Hematol"},{"key":"2703_CR20","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1038\/s41375-020-0826-9","volume":"34","author":"R Hehlmann","year":"2020","unstructured":"Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, et al. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia. 2020;34:2074\u201386.","journal-title":"Leukemia"},{"key":"2703_CR21","volume":"71","author":"M Decamp","year":"2023","unstructured":"Decamp M, Klein E, Godon C, Lestringant V, Roynard P, Theisen O, et al. Cytogenetics in the management of myeloproliferative neoplasms, mastocytosis and myelodysplastic\/myeloproliferative neoplasms: Guidelines from the Group Francophone de Cytog\u00e9n\u00e9tique H\u00e9matologique (GFCH). Curr Res Transl Med. 2023;71:103424.","journal-title":"Curr Res Transl Med"},{"key":"2703_CR22","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1080\/10428194.2023.2255804","volume":"64","author":"C Ielo","year":"2023","unstructured":"Ielo C, Scalzulli E, Carmosino I, Pepe S, Bisegna ML, Martelli M, et al. Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice. Leuk Lymphoma. 2023;64:2324\u20136.","journal-title":"Leuk Lymphoma"},{"key":"2703_CR23","doi-asserted-by":"crossref","unstructured":"Lekovic D, Gotic M, Milic N, Zivojinovic B, Jovanovic J, Colovic N, et al. Predictive parameters for imatinib failure in patients with chronic myeloid leukemia. Hematology. 2017 Mar 22;1\u20137.","DOI":"10.1080\/10245332.2017.1302179"},{"key":"2703_CR24","doi-asserted-by":"publisher","unstructured":"Vasconcelos AP, Azevedo IF, Melo FCBC, Neves WB, Azevedo ACAC, Melo RAM BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia. Genet Mol Res. 2017;16. https:\/\/doi.org\/10.4238\/gmr16029541.","DOI":"10.4238\/gmr16029541"},{"key":"2703_CR25","doi-asserted-by":"publisher","first-page":"33016","DOI":"10.18632\/oncotarget.9108","volume":"7","author":"M Culen","year":"2016","unstructured":"Culen M, Borsky M, Nemethova V, Razga F, Smejkal J, Jurcek T, et al. Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects. Oncotarget. 2016;7:33016\u201324.","journal-title":"Oncotarget"},{"key":"2703_CR26","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","volume":"99","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024;99:2191\u2013212.","journal-title":"Am J Hematol"},{"key":"2703_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","volume":"126","author":"S Sau\u00dfele","year":"2015","unstructured":"Sau\u00dfele S, Krau\u00df MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. Blood. 2015;126:42\u20139.","journal-title":"Blood"},{"key":"2703_CR28","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.3324\/haematol.2011.041251","volume":"96","author":"M Breccia","year":"2011","unstructured":"Breccia M, Latagliata R, Stagno F, Luciano L, Gozzini A, Castagnetti F, et al. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica. 2011;96:1457\u201361.","journal-title":"Haematologica"},{"key":"2703_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41375-023-02080-y","volume":"38","author":"G Rosti","year":"2024","unstructured":"Rosti G, Br\u00fcmmendorf TH, Gjertsen BT, Giraldo-Castellano P, Castagnetti F, Gambacorti-Passerini C, et al. Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study. Leukemia. 2024;38:126\u201335.","journal-title":"Leukemia"},{"key":"2703_CR30","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/ejh.13110","volume":"101","author":"R Latagliata","year":"2018","unstructured":"Latagliata R, Breccia M, Carmosino I, Cesini L, De Benedittis D, Mohamed S, et al. Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. Eur J Haematol. 2018;101:578\u201384.","journal-title":"Eur J Haematol"},{"key":"2703_CR31","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1038\/s41375-022-01648-4","volume":"36","author":"L Sch\u00f6nfeld","year":"2022","unstructured":"Sch\u00f6nfeld L, Rinke J, Hinze A, Nagel SN, Sch\u00e4fer V, Schenk T, et al. ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. Leukemia. 2022;36:2242\u20139.","journal-title":"Leukemia"},{"key":"2703_CR32","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.3324\/haematol.2018.200220","volume":"104","author":"G Nteliopoulos","year":"2019","unstructured":"Nteliopoulos G, Bazeos A, Claudiani S, Gerrard G, Curry E, Szydlo R, et al. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors. Haematologica. 2019;104:2400\u20139.","journal-title":"Haematologica"},{"key":"2703_CR33","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1182\/bloodadvances.2023012127","volume":"8","author":"MA Perusini","year":"2024","unstructured":"Perusini MA, \u017d\u00e1\u010dkov\u00e1 D, Kim T, Pagnano K, Pavlovsky C, Je\u017e\u00ed\u0161kov\u00e1 I, et al. Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes. Blood Adv. 2024;8:2361\u201372.","journal-title":"Blood Adv"},{"key":"2703_CR34","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/ajh.27553","volume":"100","author":"H Guerineau","year":"2025","unstructured":"Guerineau H, Cayuela J, Dulucq S, Tran Quang V, Tarfi S, Gricourt G, et al. Mutation of Epigenetic Regulators At Diagnosis Is An Independent Predictor Of Tyrosine Kinase Inhibitor Treatment Failure In Chronic Myeloid Leukemia: A Report From the RESIDIAG study. Am J Hematol. 2025;100:507\u201310.","journal-title":"Am J Hematol"},{"key":"2703_CR35","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.htct.2018.11.005","volume":"41","author":"GR Bosi","year":"2019","unstructured":"Bosi GR, Fogliatto LM, Costa TEV, Grokoski KC, Pereira MP, Bugs N, et al. What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?. Hematol Transfus Cell Ther. 2019;41:222\u20138.","journal-title":"Hematol Transfus Cell Ther"},{"key":"2703_CR36","unstructured":"Harrell, FE. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis [Internet]. Cham: Springer International Publishing; 2015 [cited 2025 Apr 14]. (Springer Series in Statistics). Available from: https:\/\/link.springer.com\/10.1007\/978-3-319-19425-7"},{"key":"2703_CR37","unstructured":"Hair JF, Black WC, Babin BJ, Anderson RE. Multivariate data analysis. 7. Auflage, Pearson new internat. ed. Harlow: Pearson; 2014. 1 p. (ProQuest Ebook Central)."},{"key":"2703_CR38","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1182\/blood.V87.12.5384.bloodjournal87125384","volume":"87","author":"J Hasford","year":"1996","unstructured":"Hasford J, Baccarani M, Hehlmann R, Anseri H, Tura S, Zuffa E. Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha [letter]. Blood. 1996;87:5384\u201391.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02703-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02703-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02703-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:12:10Z","timestamp":1758787930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02703-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2703"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02703-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Consent to participate by signed informed consent was obtained from all patients included in the study. The CML Observatory has been authorized (authorization no. 914456) by CNIL, the French data protection authority, in accordance with its ethical standards and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. It is promoted by the Clermont-Ferrand University Hospital, that is the coordinating center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical declarations"}}]}}